Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis.

Zhang, Ning; Zhang, Changqing; Zeng, Zhihong; Zhang, Jiyong; Du, Shengnan; Bao, Chunde; Wang, Zhe

Zhang, Ning; Zhang, Changqing; Zeng, Zhihong; Zhang, Jiyong; Du, Shengnan; Bao, Chunde; Wang, Zhe.

Afiliación

Zhang N; Longwood Biopharmaceuticals, Shanghai, People's Republic of China.
Zhang C; Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai, People's Republic of China.
Zeng Z; Longwood Biopharmaceuticals, Shanghai, People's Republic of China.
Zhang J; Longwood Biopharmaceuticals, Shanghai, People's Republic of China.
Du S; Longwood Biopharmaceuticals, Shanghai, People's Republic of China.
Bao C; Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Wang Z; Longwood Biopharmaceuticals, Shanghai, People's Republic of China.

J Inflamm Res ; 14: 2133-2147, 2021.

Article en En | MEDLINE | ID: mdl-34054304

Palabras clave

JAK1 inhibitor; mouse CIA; rat-AIA model; rheumatoid arthritis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Inflamm Res Año: 2021 Tipo del documento: Article Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google